Valuation: Indivior

Market Cap 4.61B 3.95B 3.69B 3.39B 6.37B 440B 6.47B 43.55B 17.05B 221B 17.3B 16.92B 730B P/E 2026 *
10.5x
P/E 2027 * 9.51x
Enterprise Value 4.59B 3.94B 3.68B 3.38B 6.35B 439B 6.45B 43.43B 17.01B 220B 17.25B 16.88B 728B EV / Sales 2026 *
3.45x
EV / Sales 2027 * 2.88x
Free-Float
97.98%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%+1.57% - - 4.61B
+4.46%+4.92%+82.07%+134.31% 1,141B
+0.85%+4.81%+53.77%+58.51% 659B
+2.72%+6.92%+28.99%+77.15% 470B
+0.88%+2.24%+41.16%+45.65% 366B
+0.06%+2.78%+24.25%+41.31% 302B
-0.41%+2.48%+0.18%+12.40% 254B
+4.02%+6.29%+49.67%+68.96% 239B
+0.35%+0.84%-12.98%-52.31% 207B
+2.90%+8.63%+25.11%+94.52% 183B
Average +0.96%+4.10%+32.47%+53.39% 424.55B
Weighted average by Cap. +0.59%+4.31%+46.83%+74.17%

Financials

2026 *2027 *
Net sales 1.33B 1.14B 1.07B 979M 1.84B 127B 1.87B 12.59B 4.93B 63.85B 5B 4.89B 211B 1.4B 1.2B 1.12B 1.03B 1.93B 134B 1.97B 13.23B 5.18B 67.09B 5.25B 5.14B 222B
Net income 474M 407M 380M 349M 655M 45.33B 666M 4.48B 1.76B 22.74B 1.78B 1.74B 75.17B 530M 455M 424M 389M 732M 50.65B 744M 5.01B 1.96B 25.41B 1.99B 1.95B 84B
Net Debt -12.5M -10.72M -10.01M -9.19M -17.27M -1.19B -17.56M -118M -46.26M -599M -46.94M -45.91M -1.98B -570M -489M -457M -419M -788M -54.48B -801M -5.39B -2.11B -27.32B -2.14B -2.09B -90.34B
Logo Indivior
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-